| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALNY | Common Stock | Award | $0 | +3.28K | $0.00 | 3.28K | Apr 26, 2023 | Direct | F1 | |
| transaction | ALNY | Common Stock | Sale | -$23.6K | -122 | -3.72% | $193.18 | 3.16K | Apr 27, 2023 | Direct | F2, F3 |
| transaction | ALNY | Common Stock | Sale | -$109K | -562 | -17.81% | $193.93 | 2.59K | Apr 27, 2023 | Direct | F2, F4 |
| transaction | ALNY | Common Stock | Sale | -$122K | -625 | -24.1% | $194.94 | 1.97K | Apr 27, 2023 | Direct | F2, F5 |
| transaction | ALNY | Common Stock | Sale | -$12.5K | -64 | -3.25% | $195.65 | 1.9K | Apr 27, 2023 | Direct | F2, F6 |
| transaction | ALNY | Common Stock | Sale | -$20.3K | -103 | -5.41% | $197.08 | 1.8K | Apr 27, 2023 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS). |
| F2 | Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. |
| F3 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F4 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F5 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F6 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |